This information was published on 2019-06-18T08:51:35 for IP Right Registration Published.
| Field | Value |
| (210) | 1967554 |
| (220) |
08 Nov 2018
|
| (300) |
US, 16 May 2018, 87924237
|
| (511) (510) |
Class 5
Pharmaceutical preparations for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Oligonucleotide compounds for use in the targeted delivery of RNAi therapy; Pharmaceutical preparations for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; Chemical compounds in the form of a molecular nanoparticle complex that act as a platform for the delivery of RNA-based drugs to biological cells; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies Class 42 Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of various diseases, namely, rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, cancers, and viral infections; research and development of pharmaceutical preparations for the treatment of liver-based disorders; research and development of oligonucleotide compounds for targeted gene silencing; scientific research and development; scientific investigations for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials |
| (540) | DICERNA |
| (550) | Word |
| (730) |
Dicerna Pharmaceuticals, Inc.
|
| (750) |
Pizzeys Patent and Trade Mark Attorneys Pty Ltd
|
Find out more about publications on the About page.